These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 16792672)

  • 1. Soluble CD26/CD30 levels in visceral leishmaniasis: markers of disease activity.
    Ajdary S; Riazi-Rad F; Jafari-Shakib R; Mohebbali M
    Clin Exp Immunol; 2006 Jul; 145(1):44-7. PubMed ID: 16792672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble CD26 and CD30 levels in patients with anthroponotic cutaneous leishmaniasis.
    Ajdary S; Jafari-Shakib R; Riazi-Rad F; Khamesipour A
    J Infect; 2007 Jul; 55(1):75-8. PubMed ID: 17241668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum and CSF soluble CD26 and CD30 concentrations in healthy pediatric surgical outpatients.
    Delezuch W; Marttinen P; Kokki H; Heikkinen M; Vanamo K; Pulkki K; Matinlauri I
    Tissue Antigens; 2012 Oct; 80(4):368-75. PubMed ID: 22861386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of serum-soluble CD26 and CD30 levels with asthma, lung function and bronchial hyper-responsiveness at school age.
    Remes ST; Delezuch W; Pulkki K; Pekkanen J; Korppi M; Matinlauri IH
    Acta Paediatr; 2011 Sep; 100(9):e106-11. PubMed ID: 21401715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble CD26 and CD30 levels in patients with common variable immunodeficiency.
    Mahmoudi M; Hedayat M; Aghamohammadi A; Rezaei N
    J Investig Allergol Clin Immunol; 2013; 23(2):120-4. PubMed ID: 23654079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma sCD26 and sCD30 levels in cutaneous leishmaniasis.
    Jafari-Shakib R; Shokrgozar MA; Nassiri-Kashani M; Malakafzali B; Nikbin B; Khamesipour A
    Acta Trop; 2009 Jan; 109(1):61-3. PubMed ID: 18983807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impaired expression of CD26 compromises T-cell recruitment in human visceral leishmaniasis.
    Rai AK; Thakur CP; Kumar P; Mitra DK
    Eur J Immunol; 2012 Oct; 42(10):2782-91. PubMed ID: 22806538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum levels of soluble CD26 and CD30 in patients on hemodialysis.
    Nakao K; Nagake Y; Okamoto A; Ichikawa H; Yamamura M; Makino H
    Nephron; 2002 Jun; 91(2):215-21. PubMed ID: 12053056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble CD30 is more relevant to disease activity of atopic dermatitis than soluble CD26.
    Katoh N; Hirano S; Suehiro M; Ikenaga K; Yamashita T; Sugawara N; Yasuno H
    Clin Exp Immunol; 2000 Aug; 121(2):187-92. PubMed ID: 10931130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid detection of human and canine visceral leishmaniasis: assessment of a latex agglutination test based on the A2 antigen from amastigote forms of Leishmania infantum.
    Akhoundi B; Mohebali M; Shojaee S; Jalali M; Kazemi B; Bandehpour M; Keshavarz H; Edrissian GH; Eslami MB; Malekafzali H; Kouchaki A
    Exp Parasitol; 2013 Mar; 133(3):307-13. PubMed ID: 23276878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indoleamine 2,3-dioxygenase activity as a potential biomarker of immune suppression during visceral leishmaniasis.
    Gangneux JP; Poinsignon Y; Donaghy L; Amiot L; Tarte K; Mary C; Robert-Gangneux F
    Innate Immun; 2013 Dec; 19(6):564-8. PubMed ID: 23413147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serological evaluation of experimentally infected dogs by LicTXNPx-ELISA and amastigote-flow cytometry.
    Silvestre R; Santarém N; Cunha J; Cardoso L; Nieto J; Carrillo E; Moreno J; Cordeiro-da-Silva A
    Vet Parasitol; 2008 Nov; 158(1-2):23-30. PubMed ID: 18848397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement in lung function is associated with a decrease in serum soluble CD30 in atopic infants.
    Kotaniemi-Syrjänen A; Delezuch W; Pelkonen AS; Malmström K; Malmberg LP; Punnonen K; Matinlauri IH; Mäkelä MJ
    Ann Allergy Asthma Immunol; 2015 Feb; 114(2):156-7. PubMed ID: 25492095
    [No Abstract]   [Full Text] [Related]  

  • 14. Development and evaluation of Leishmania infantum rK26 ELISA for serodiagnosis of visceral leishmaniasis in Iran.
    Farajnia S; Darbani B; Babaei H; Alimohammadian MH; Mahboudi F; Gavgani AM
    Parasitology; 2008 Aug; 135(9):1035-41. PubMed ID: 18561868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum chemokine profiles in visceral leishmaniasis, HIV and HIV/ visceral leishmaniasis co-infected Ethiopian patients.
    Sisay Z; Berhe N; Petros B; Tegbaru B; Messele T; Hailu A; Wolday D
    Ethiop Med J; 2011 Jul; 49(3):179-86. PubMed ID: 21991751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in plasma soluble CD26 and CD30 during pregnancy: markers of Th1/Th2 balance?
    Hoshimoto K; Ohta N; Ohkura T; Inaba N
    Gynecol Obstet Invest; 2000; 50(4):260-3. PubMed ID: 11093050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotypes of the mannan-binding lectin gene and susceptibility to visceral leishmaniasis and clinical complications.
    Alonso DP; Ferreira AF; Ribolla PE; de Miranda Santos IK; do Socorro Pires e Cruz M; Aécio de Carvalho F; Abatepaulo AR; Lamounier Costa D; Werneck GL; Farias TJ; Soares MJ; Costa CH
    J Infect Dis; 2007 Apr; 195(8):1212-7. PubMed ID: 17357060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Interpretation of laboratory data during cryptic leishmaniasis in dog].
    Gravino AE
    Parassitologia; 2004 Jun; 46(1-2):227-9. PubMed ID: 15305723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of noninvasive markers to detect Leishmania infection in asymptomatic human immunodeficiency virus-infected patients.
    García-García JA; Martín-Sánchez J; Gállego M; Rivero-Román A; Camacho A; Riera C; Morillas-Márquez F; Vergara S; Macías J; Pineda JA
    J Clin Microbiol; 2006 Dec; 44(12):4455-8. PubMed ID: 17050814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
    Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G
    Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.